Novavax Q2 EPS $0.58 Beats $(1.24) Estimate, Sales $424.43M Beat $257.62M Estimate
Portfolio Pulse from Benzinga Newsdesk
Novavax reported Q2 earnings of $0.58 per share, beating the analyst consensus estimate of $(1.35) by 142.96%. This is a 108.88% increase over losses of $(6.53) per share from the same period last year. The company also reported quarterly sales of $424.43 million, beating the analyst consensus estimate of $237.39 million by 78.79%. This is a 128.28% increase over sales of $185.93 million the same period last year.
August 08, 2023 | 10:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novavax's Q2 earnings and sales significantly beat estimates, indicating strong financial performance. This could potentially lead to a positive impact on the company's stock price.
Novavax's Q2 earnings and sales significantly exceeded analyst estimates, which is typically a positive signal for investors and can lead to an increase in the company's stock price. The company's earnings increased by 108.88% and sales increased by 128.28% compared to the same period last year, indicating strong financial performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100